schizandrin b has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Finlay, MR; Griffin, RJ | 1 |
| Hu, X; Lu, Q; Qiangrong, P; Wang, T | 1 |
| Wang, G; Wang, J; Wang, Y; Wei, J; Yang, J; Zhang, J | 1 |
2 review(s) available for schizandrin b and Neoplasms
| Article | Year |
|---|---|
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.
Topics: Glycogen Synthase Kinase 3 beta; Humans; Neoplasms | 2022 |
1 other study(ies) available for schizandrin b and Neoplasms
| Article | Year |
|---|---|
Schisandrin B--a novel inhibitor of P-glycoprotein.
Topics: Affinity Labels; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Cell Line, Tumor; Cell Proliferation; Cyclooctanes; Daunorubicin; Dihydropyridines; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Humans; Inhibitory Concentration 50; K562 Cells; Lignans; Models, Chemical; Neoplasms; Polycyclic Compounds; Protein Binding; Tetrazolium Salts; Thiazoles; Time Factors | 2005 |